Expression of P-Akt, NFκB and their correlation with human papillomavirus infection in cervical carcinoma

Purpose: To investigate the expression of P-Akt and NF kappa B and their correlation with human papillomavirus (HPV) infection in cervical carcinoma. Material and Methods: Expression of P-Akt and NF kappa B was detected by an immunohistochemical SP technique with HPV DNA detetion by PCR in 26 cases of cervical carcinoma tisuues, 18 cases of cervical intraepithelial neoplasia tisuues (CINI / n = 5, CINII / n = 3, CINIII / n = 10) and 19 cases of chronic cervicitis tissues. The different expressions of P-Akt and NF kappa B were compared in different pathological types of cervical carcinoma (cervical squamous cell carcinoma, cervical adenocarcinoma), different pathological grading (high, medium, poorly differentiated) and different clinical stage (FIGO I to IV). The relationships between P-Akt and NF kappa B, respectively, with HPV infection in cervical carcinoma were analyzed. Results: The positive expression rate of P-Akt in chronic cervicitis tissues, CIN and cervical carcinoma tisuues was 21.05%, 66.67%, and 92.31%, respectively. There was no obvious difference in the expression of P-Akt in cervical carcinoma in different pathological types or in pathological grading and no obvious difference in different clinical stages. The positive expression rate of NF kappa B in chronic cervicitis tissues, CIN and cervical carcinoma tissues was 10.52%, 72.22% and 96.15%, respectively; there was no statistically significant difference among the groups for different pathological types and there was no obvious difference in different pathological grading or different clinical stage. There was an obviously positive correlation between P-Akt and NF kappa B expression rate and degree of disease (r = 0.998, p < 0.05). Cervical carcinoma and CIN cases totaled 44; the positive expression rate of P-Akt was 87.55% in 32 cases of positive HPV-DNA of the 44 cases, and the positive expression rate of P-Akt was only 16.70% in 12 cases of negative HPV-DNA of the 44 cases. The positive expression rate of NF kappa B was obviously higher in the HPV DNA positive than in the HPV-DNA negative cases. There was a statistically significant difference among the groups (p < 0.05). Conclusion: The positive expression rate of P-Akt and NF kappa B was closely related with cervical disease extent, and closely related with HPV infection in cervical carcinoma. This study suggests that P-Akt and NF kappa B more probably play an important role in the occurrence of cervical carcinoma.

Cervical carcinoma; P-Akt; NFκB; Human papilloma virus

[1] Parkin D.M., Pisani P., Ferlay J.: “Global cancer statistics”. Carcinoma J. Clin., 1999, 49, 33.

[2] Cao Z.Y.: “Common gynecological carcinoma treatment guidelines”. 3rd edition. Beijing: People’s Health Press, 2010, 23.

[3] Pianetti S., Arsura M., Romieu-Mourez R., Coffey R.J., Sonenshein G.E.: “Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of Ikappa B-alpha that can be inhibited by the tumor suppressor PTEN”. Oncogene, 2001, 20, 1287.

[4] Malik S.N., Brattain M., Ghosh P.M., Troyer D.A., Prihoda T., Bedolla R., Kreisberg J.I.: “Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer”. Clin. Cancer Res., 2002, 8, 1168.

[5] Yu L.L., Dai N., Yu H.G., Sun L.M., Si J.M.: “Akt associates with nuclear factor KappaB and plays an important role in chemoresistance of gastric carcinoma cells”. Oncol. Rep., 2010, 24, 113.

[6] Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M.: “PI3K/Akt signalling pathway and cancer”. Carcinoma Treat. Rev., 2004, 30, 193.

[7] Ma Y.Y., Wei S.J., Lin Y.C., Lung J.C., Chang T.C., Whang-Peng J. et al.: “PIK3CA as an oncogene in cervical carcinoma”. Oncogene, 2000, 19, 2739.

[8] Kang S., Bader A.G., Vogt P.K.: “Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic”. Proc. Natl. Acad. Sci. USA, 2005, 102, 802.

[9] Rao P.H., Arias-Pulido H., Lu X.Y., Harris C.P., Vargas H., Zhang F.F. et al.: “Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma”. BMC Cancer, 2004, 6, 4.

[10] García M.G., Alaniz L.D., Cordo Russo R.I., Alvarez E., Hajos S.E.: “PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines”. Leuk. Res., 2009, 33, 288.

[11] Gilmore T.D.: “Introduction to NF-kappaB: players pathways perspectives”. Oncogene 2006, 25, 6680.

[12] Seheidereit C.: “IkappaB kinase complexes: gateways to NFkappaB activation and transcription”. Oncogene, 2006, 25, 6685.

[13] Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L. et al.: “Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy”. Leukemia, 2003, 17, 590.

[14] Cai H.B., Ding X.H., Zhou Y.F., Lie D.M.: “Risk factors for cervical cancer in China: a case-control study”. Eur. J. Gynaecol. Oncol., 2008, 1, 72.

[15] Kim S.H., Juhnn Y.S., Kang S., Park S.W., Sung M.W., Bang Y.J. et al.: “Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1 2 and PI3K Akt”. Cell. Mol. Life Scie., 2006, 63, 930.

[16] Menges C.W., Baglia L.A., Lapoint R., McCance D.J.: “Human papillomavirus type 16 E7 Up-regulates AKT Activity through the retinoblastoma protein”. Cancer Res., 2006, 66, 5555.

[17] Havard L., Rahmouni S., Boniver J., Delvenne P.: “High levels of p105 (NFκBl) and p100 (NFκB 2) proteins in HPVl6-transformed keratinocytes role of E 6 and E 7 oncoproteins”. Virology, 2005, 331, 357.